Comparison of topical 3% diclofenac sodium gel and 5% imiquimod cream for the treatment of actinic keratoses

Clinical and Experimental Dermatology

Volumn 36, Issue 5, 2011, Pages 479-484

  Akarsu, S ^a   Aktan, Ş ^a   Atahan, A ^a   Koc P ^a   Özkan, Ş ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ACTINOMA GEL; ALDARA CREAM; DICLOFENAC; IMIQUIMOD; UNCLASSIFIED DRUG;

ACTINIC KERATOSIS; ADULT; AGED; ARTICLE; CLEARANCE; CLINICAL ASSESSMENT TOOL; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CREAM; DRUG EFFECT; DRUG EFFICACY; EROSION; ERYTHEMA; FEMALE; FOLLOW UP; GEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT GLOBAL IMPROVEMENT INDEX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SKIN EDEMA; TOTAL THICKNESS SCORE; TREATMENT OUTCOME; XERODERMA;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; AGED, 80 AND OVER; AMINOQUINOLINES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; DICLOFENAC; FEMALE; GELS; HUMANS; KERATOSIS, ACTINIC; MALE; MIDDLE AGED; OINTMENTS; SINGLE-BLIND METHOD; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 79959352251     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2010.03999.x     Document Type: Article

References (20)

1. Berman B, Bienstock L, Kuritzky L et al. Actinic keratosis: sequelae and treatments. Recommendations from a consensus panel. J Fam Pract 2006; 55: S1-8.
2. de Berker D, McGregor JM, Hughes BR, British Association of Dermatologists Therapy Guidelines and Audit Subcommittee. Guidelines for the management of actinic keratoses. Br J Dermatol 2007; 156: 222-30.
3. Lober BA, Fenske NA. Optimum treatment strategies for actinic keratosis (intraepidermal squamous cell carcinoma). Am J Clin Dermatol 2004; 5: 395-401.
4. Rivers JK, McLean DI. An open study to assess the efficacy and safety of topical 3% diclofenac in a 2.5% hyaluronic acid gel for the treatment of actinic keratosis. Arch Dermatol 1997; 133: 1239-42.
5. Rivers JK, Wolf J. Assessing clinically meaningful end points for the management of actinic keratosis with diclofenac 3% gel. Acta Derm Venereol 2007; 87: 286.
6. Merk HF. Topical diclofenac in the treatment of actinic keratoses. Int J Dermatol 2007; 46: 12-18.
7. Rivers JK, Arlette J, Shear N et al. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluranon gel. Br J Dermatol 2002; 146: 94-100.
8. Wolf JE Jr, Taylor JR, Tschen E et al. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol 2001; 40: 709-13.
9. Nelson C, Rigel D, Smith S et al. Phase IV, open-label assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel (Solaraze). J Drugs Dermatol 2004; 3: 401-7.
10. McEwan LE, Smith JG. Topical diclofenac/hyaluronic acid gel in the treatment of solar keratoses. Australas J Dermatol 1997; 38: 187-9.
11. Szeimies RM, Gerritsen MJ, Gupta G et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol 2004; 51: 547-55.
12. Hadley G, Derry S, Moore RA. Imiquimod for actinic keratosis: systematic review and meta-analysis. J Invest Dermatol 2006; 126: 1251-5.
13. Salasche SJ, Levine N, Morrison L. Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: an open label trial. J Am Acad Dermatol 2002; 47: 571-7.
14. Lebwohl M, Dinehart S, Whiting D et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 2004; 50: 714-21.
15. Lee PK, Harwell WB, Loven KH et al. Long-term clinical outcomes following treatment of actinic keratosis with imiquimod 5%. Dermatol Surg 2005; 31: 659-64.
16. Korman N, Moy R, Ling M et al. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol 2005; 141: 467-73.
17. Tran H, Chen K, Shumack S. Summary of actinic keratosis studies with imiquimod 5% cream. Br J Dermatol 2003; 149: 37-9.
18. Krawtchenko N, Roewert-Huber J, Ulrich M et al. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol 2007; 157: 34-40.
19. Smith SR, Morhenn VB, Piacquadio DJ. Bilateral comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% 5-fluorouracil cream in the treatment of actinic keratoses of the face and scalp. J Drugs Dermatol 2006; 5: 156-9.
20. Kose O, Koc E, Erbil AH et al. Comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% imiquimod cream in the treatment of actinic keratosis. J Dermatolog Treat 2008; 19: 159-63.